Serious Game-based Interventions in Patients With Mild Cognitive Impairment Outside the Clinic
Launched by UNIVERSITY OF MASSACHUSETTS, AMHERST · Jun 3, 2021
Trial Information
Current as of May 09, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying the effectiveness of a set of cognitive training games called Neuro-World, designed specifically for patients with mild cognitive impairment. The goal is to see if playing these games can help improve thinking skills in individuals aged 55 and older. If someone has a score between 17 and 25 on a test called the Montreal Cognitive Assessment (MoCA), they might be eligible to join the study, as long as they are comfortable using a tablet and have access to a computer for online meetings.
Participants in the trial will engage in these games from the comfort of their own homes, making it a convenient option. It’s important to note that people with certain medical conditions, such as severe depression, dementia, or significant problems with their hands that make it hard to use a tablet, will not be eligible to participate. Overall, this study aims to explore a fun and innovative way to support cognitive health in older adults experiencing mild cognitive impairments.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Seventeen points or greater and smaller than twenty-six points on the Montreal Cognitive Assessment (MoCA)
- • Fifty-five years old and above
- • Minimal technological literacy (i.e. ability to use a tablet independently)
- • Having a computer for online videoconferencing-based communication (necessary for online cognitive assessments)
- Exclusion Criteria:
- • Confounding neurological and psychiatric disorders
- • History of traumatic brain injury
- • Clinically known hearing or vision impairment
- • Severe upper-limb motor impairments that could impact the use of mobile devices
- • Clinical presentations suggestive of dementia with Lewy bodies, progressive supranuclear palsy, multiple system atrophy, or vascular parkinsonism
- • Diagnosis of dementia
- • Major depression
- • Any significant upper-limb impairment that could affect tablet use
- • Participation in any other therapist-supervised cognitive training
About University Of Massachusetts, Amherst
The University of Massachusetts Amherst is a leading research institution dedicated to advancing knowledge and improving public health through innovative clinical trials. With a strong emphasis on interdisciplinary collaboration, the university leverages its expertise in biomedical research, social sciences, and engineering to address pressing health challenges. UMass Amherst is committed to conducting rigorous and ethical clinical studies that contribute to the development of effective therapies and interventions, ultimately enhancing patient care and community well-being. The university's state-of-the-art facilities and experienced research teams support a diverse portfolio of clinical trials, fostering an environment of discovery and excellence in medical research.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Amherst, Massachusetts, United States
Newark, New Jersey, United States
Patients applied
Trial Officials
Sunghoon I Lee, PhD
Principal Investigator
University of Massachusetts, Amherst
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials